Clinical Trials Logo
  1. Home
  2. Narcolepsy Type 1
  3. NCT06358950

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) — Vibrance-1  

Narcolepsy Type 1 Clinical Trial

Official title:
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

Clinical Trial Summary

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06358950
Study type Interventional
Source Alkermes, Inc.
Contact Global Clinical Services
Phone US: 888-235-8008
Email clinicaltrials@alkermes.com
Status Recruiting
Phase Phase 2
Start date March 28, 2024
Completion date July 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05983731 - A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
Suspended NCT04419792 - 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Completed NCT05375890 - Clinical and Neurophysiological Characteristics of Narcolepsy
Not yet recruiting NCT06292598 - Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
Not yet recruiting NCT06457945 - Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions N/A
Not yet recruiting NCT06383806 - Decreasing Nightmares in Adults With Narcolepsy N/A
Not yet recruiting NCT05914194 - A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 Phase 3
Completed NCT05687903 - A Study of TAK-861 in Participants With Narcolepsy Type 1 Phase 2
Recruiting NCT05967832 - Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy N/A
Completed NCT05709873 - Narcolepsy Nightmare Study N/A
Recruiting NCT04483310 - Meditation-Relaxation (MR Therapy) for Sleep Paralysis. N/A
Completed NCT04445129 - Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
Completed NCT05460052 - Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
Completed NCT05314556 - Group Psychotherapy in Narcolepsy Type 1 N/A
Recruiting NCT05816382 - A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions Phase 2/Phase 3
Recruiting NCT06336057 - Mentalizating in Adults Suffering From Narcolepsy Type 1.
Recruiting NCT06251063 - Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence N/A
Completed NCT06241911 - Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1 N/A